ethyl 2-(nicotinamido)-4,5,6,7-tetrahydrobenzo[b]thiophene-3-carboxylate | 62349-06-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: ethyl 2-(nicotinamido)-4,5,6,7-tetrahydrobenzo[b]thiophene-3-carboxylate
• 英文别名: 2-nicotinoylamino-4,5,6,7-tetrahydro-benzo[b]thiophene-3-carboxylic acid ethyl ester；Ethyl 2-(pyridine-3-carbonylamino)-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxylate
• CAS: 62349-06-8
• 化学式: C₁₇H₁₈N₂O₃S
• mdl: MFCD00391999
• 分子量: 330.408
• InChiKey: KWJSVZXQWFVHQO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  23
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  96.5
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  ethyl 2-(nicotinamido)-4,5,6,7-tetrahydrobenzo[b]thiophene-3-carboxylate 在 N,N-二异丙基乙胺 、 O-(benzotriazol-1-yl)-N,N,N,N-tetramethyluroniumhexafluorophosphate 、 lithium hydroxide 作用下， 以 四氢呋喃 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 14.0h， 生成 N-(3-((4-methoxybenzyl)carbamoyl)-4,5,6,7-tetrahydrobenzo[b]thiophen-2-yl)nicotinamide
  参考文献：
  名称：

  New cycloalkyl[b]thiophenylnicotinamide-based α-glucosidase inhibitors as promising anti-diabetic agents: Synthesis, in silico study, in vitro and in vivo evaluations

  摘要：

  DOI：

  10.1016/j.bmcl.2022.129069
• 作为产物：
  描述：

  环己酮 、 氰乙酸乙酯 在 吗啉 、 1,2,3,4,5,6,7,8-八硫杂环辛烷 、 三乙胺 作用下， 以 乙醇 、 二氯甲烷 为溶剂， 反应 17.0h， 生成 ethyl 2-(nicotinamido)-4,5,6,7-tetrahydrobenzo[b]thiophene-3-carboxylate
  参考文献：
  名称：

  New cycloalkyl[b]thiophenylnicotinamide-based α-glucosidase inhibitors as promising anti-diabetic agents: Synthesis, in silico study, in vitro and in vivo evaluations

  摘要：

  DOI：

  10.1016/j.bmcl.2022.129069

文献信息

• 3-Amino-thieno- und -[1]benzothieno[2,3-d]pyrimidin-derivate
  作者：Fritz Sauter、Peter Stanetty、Hans Potužak

  DOI：10.1002/ardp.19763091109

  日期：——

  In 2‐Stellung basisch substituierte Derivate des 3‐Amino‐thieno[2,3‐d]pyrimidin‐4(3H)‐ons (allg. Formel I) sowie des 3‐Amino‐5.6.7.8‐tetrahydro‐[1]benzothieno[2,3‐d]pyrimidin‐4(3H)‐ons (allg. Formel II) wurden dadurch synthetisiert, daß die entsprechend substituierten 2‐Acylamino‐thiophen‐ (bzw. ‐benzo[b]thiophen‐) carbonsäureester 1a–1o hergestellt und diese mittels Hydrazin in einer einstufigen Reaktion

  3-氨基-噻吩并[2,3-d]嘧啶-4(3H)-one（通式I）和3-氨基-5.6.7.8-四氢-[1]苯并噻吩的衍生物在2-中具有碱性取代基[2,3-d] 嘧啶-4 (3H) -ones（通式II）是通过相应取代的2-酰氨基-噻吩-（或-苯并[b]噻吩-）羧酸酯1a合成的– 1o 和这些在一步反应中使用肼进行取代和环化，得到目标化合物。
• Novel therapeutic targets for the treatment of mycobacterial infections and compounds useful therefor
  申请人：——

  公开号：US20040171603A1

  公开（公告）日：2004-09-02

  Described herein is the discovery that certain mycobacterial serine/threonine protein kinases, particularly protein kinase G (PknG), are effective therapeutic targets for the treatment of mycobacterial infections. Furthermore, the present application refers to the use of mycobacterial serine/threonine protein kinases for developing methods for detection and determination of these kinases for recognizing and monitoring diseases and for controlling therapy of diseases. Additionally disclosed are novel 4,5,6,7-tetrahydrobenzo[b]thiophene compounds, benzo(g)quinoxaline compounds, and pharmaceutically acceptable salts thereof, and methods of using such compounds and salts thereof for the prophylaxis and/or treatment of virally and/or bacterially induced infections, particularly mycobacteria-induced infections, including opportunistic infections, as well as pharmaceutical compositions containing at least one 4,5,6,7-tetrahydrobenzo[b]thiophene compound and/or benzo(g)quinoxaline compound and/or pharmaceutically acceptable salts thereof in a pharmaceutically acceptable carrier.

  本文描述的是发现某些分枝杆菌丝氨酸/苏氨酸蛋白激酶，特别是蛋白激酶 G (PknG)，是治疗分枝杆菌感染的有效治疗靶点。此外，本申请还涉及利用分枝杆菌丝氨酸/苏氨酸蛋白激酶开发检测和测定这些激酶的方法，用于识别和监测疾病以及控制疾病的治疗。此外，还公开了新型 4,5,6,7-四氢苯并[b]噻吩化合物、苯并（g）喹喔啉化合物及其药学上可接受的盐，以及使用此类化合物及其盐预防和/或治疗病毒和/或细菌引起的感染，特别是分枝杆菌引起的感染（包括机会性感染）的方法，以及含有至少一种 4,5,6,7-四氢苯并&lsqb；b]噻吩化合物和/或苯并(g)喹喔啉化合物和/或其药学上可接受的盐，并将其置于药学上可接受的载体中。
• 4,5,6,7-TRETRAHYDROBENZO(B) THIOPHENE DERIVATIVES AND METHODS FOR MEDICAL INTERVENTION AGAINST MYCROBACTERIAL INFECTIONS
  申请人：Axxima Pharmaceuticals AG

  公开号：EP1492783A1

  公开（公告）日：2005-01-05
• THIOPHENE-BASED COMPOUNDS EXHIBITING NOX4 INHIBITORY ACTIVITY AND USE THEREOF IN THERAPY
  申请人：Glucox Biotech AB

  公开号：EP2825165A1

  公开（公告）日：2015-01-21
• 4,5,6,7-tetrahydrobenzo[b]thiophene derivatives and methods for medical intervention against mycobacterial infections
  申请人：Missio Andrea

  公开号：US20090018149A1

  公开（公告）日：2009-01-15

  Described are 4,5,6,7-tetrahydrobenzo[b]thiophene derivatives and pharmaceutically acceptable salts thereof, the use of these derivatives for the prophylaxis and/or treatment of mycobacteria-induced infections and opportunistic infections, as well as compositions containing at least one 4,5,6,7-tetrahydrobenzo[b]thiophene derivative and/or pharmaceutically acceptable salts thereof. Furthermore, the present application refers to the use of mycobacterial protein serine/threonine kinases for developing methods for detection and determination of these kinases for recognising and monitoring diseases and for controlling therapy of diseases.